疫苗前沿 | 显著降低三阴性乳腺癌复发风险，Keytruda组合3期临床结果发表

 

参考资料:

[1] Pivotal Phase 3 Data for Keytruda® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine. Retrieved February 10， 2022, from https://www.merck.com/news/pivotal-phase-3-data-for-keytruda-pembrolizumab-in-high-risk-early-stage-triple-negative-breast-cancer-tnbc-published-in-the-new-england-journal-of-medicine/

[2] Schmid et al., (2022). Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. NEJM, DOI: 10.1056/NEJMoa2112651

来源：药明康德

打赏